Source: International Congress 2015 – Pulmonary fibrosis: mechanisms of disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Peter Paluch (Prague, Czech Republic), Peter Paluch, Martina Sterclova, Irena Brabcova, Ondrej Viklicky, Martina Vasakova. SMAD2 mRNA expression is upregulated in fibrosing interstitial lung diseases (ILDs). Eur Respir J 2015; 46: Suppl. 59, 934

Member's Comments

No comment yet.

Related content which might interest you: mRNA expression of YY1, TNF-α a TGF-β in lung samples gained by transbronchial biopsies (TBB) in patients with different interstitial lung diseases (ILDs) Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 B-cell infiltration varies among patients with interstitial lung diseases Source: International Congress 2016 – ILD pathogenesis Year: 2016 Genetics of fibrosing lung diseases Source: Eur Respir J 2005; 25: 915-927 Year: 2005 Circulating monocytes from interstitial lung disease patients show an activated phenotype Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Outcomes in interstitial lung diseases (ILDs) Source: Eur Respir J 2005; 26: Suppl. 49, 268s Year: 2005 αVβ6 integrin expression in interstitial lung diseases Source: Annual Congress 2009 - Sarcoidosis and profiles of other diffuse parenchymal lung disease Year: 2009 Antisynthetase syndrome (AS) in patients with diffuse interstitial lung disease (ILD) Source: International Congress 2015 – Connective tissue disorders Year: 2015 Interstital lung diseases: update 2005 Source: Annual Congress 2005 - Clinical year in review Year: 2005 Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Retinoic acid-related orphan receptor-a (Rora) expression in patients with fibrotic interstitial pneumonias: A lung tissue study Source: International Congress 2014 – IPF and surroundings Year: 2014 Clinical significance of different cytokines expression in lung tissue in idiopathic fibrosing alveolitis (IFA) and lung sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 313s Year: 2002 Inhibition of profibrotic signaling in fibroblasts from patients with idiopathic pulmonary fibrosis (IPF) by histone deacetylase-inhibitors (HDACi) or the IPF drug pirfenidone Source: International Congress 2014 – ILDs 1 Year: 2014 Increased cytokeratin-19 expression in fibrotic interstitial lung disease Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease Year: 2010 Effect of nintedanib on the release of angiogenic/angiostatic cytokines by alveolar macrophages (AMs) in interstitial lung diseases (ILD) Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Loss of PTEN induced lung fibroblasts exhibiting similar pathogenic features to cancer cells in idiopathic pulmonary fibrosis Source: International Congress 2014 – ILDs 2 Year: 2014 Effect of pirfenidone (PFD) on cytokine/chemokine release from alveolar macrophages (AMs) in interstitial lung diseases (ILD): Preliminary results Source: Annual Congress 2013 –Diffuse pulmonary fibrosis Year: 2013 Treatment of progressive fibrosing interstitial lung diseases: a milestone in the management of interstitial lung diseases Source: Eur Respir Rev, 28 (153) 190109; 10.1183/16000617.0109-2019 Year: 2019 Evaluation of romidepsin (FK228) as a potential therapy for idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – Common mechanisms in lung development and fibrosis Year: 2016 KL-6, SP-D and MMP-7 as serum biomarkers for early detection of interstitial lung diseases Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013